Drug Profile
RM 03
Alternative Names: RM-03Latest Information Update: 06 Apr 2022
Price :
$50
*
At a glance
- Originator CutisPharma
- Developer Azurity Pharmaceuticals; Dr Reddys Laboratories
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Gastrointestinal disorders
Most Recent Events
- 06 Apr 2022 Clinical development is ongoing in USA (Azurity Pharmaceuticals pipeline, April 2022)
- 12 Jun 2019 CutisPharma is now called Azurity Pharmaceuticals
- 28 May 2019 No recent reports of development identified for clinical-Phase-Unknown development in Gastrointestinal disorders in USA